CHAPEL HILL, N.C., Mar 6, 2002 /PRNewswire-FirstCall via COMTEX/ -- POZEN Inc.
(Nasdaq: POZN), a pharmaceutical development company with a portfolio of
candidates for the treatment of migraine, announced today that it has submitted
the final results of its six-month mouse carcinogencity study for its lead
product candidate, MT 100, to the Food and Drug Administration (FDA). The final
results confirmed preliminary findings that indicated that MT 100 was not
carcinogenic in the test species, p53 transgenic mice. The preliminary results
were submitted to the FDA in February.
MT 100 is being developed as an oral, first-line treatment for migraine pain and
associated symptoms. The effectiveness of the product candidate has been
demonstrated in numerous Phase II and Phase III clinical studies involving
thousands of patients. Last year the company announced that MT 100 provided
comparable efficacy with fewer incidences of side effects when tested against
Imitrex(R), the worldwide market leader.
North Carolina-based POZEN Inc. is a pharmaceutical development company
committed to building a portfolio of products with significant commercial
potential in select therapeutic areas. POZEN's initial focus is on developing
products for migraine therapy, a global market expected to exceed $2.6 billion
this year. The company's common stock is traded on The Nasdaq Stock Market under
the symbol "POZN."
Statements included in this press release that are not historical in nature are
"forward-looking statements" within the meaning of the "safe harbor" proviWe do
not intend to update any of these factors or to publicly announce the results of
any revisions to these forward-looking statements.
POZEN is on the Internet at www.pozen.com
Chief Financial Officer, of POZEN
Kathy Brunson of FRB Weber Shandwick